Global Cancer Stem Cells Market Overview:
According to SPER Market Research, the Global Cancer Stem Cells Market is estimated to reach USD 2.68 billion by 2032 with a CAGR of 10.29%.
The tumour’s other cell types are produced by the cancer cell, which has the capacity to divide and grow continuously. Cancer stem cells are believed to oversee tumour development, metastasis, and recurrence. These are the rare forms of godlike cells called cancer stem cells are found in tumours and give rise to a wide range of cell types that make up the tumour. These cells have been identified in several human tumours and may serve as targets for cancer therapy. Most anti-cancer medications function by inducing the death of cancer cells. Even though these treatments seem to be working, some individuals nonetheless have a disease recurrence. The primary driver fuelling the expansion of the cancer stem cell market is the rising incidence of cancer in the world.
Impact of COVID-19 on the Global Cancer Stem Cells Market
The cancer stem cell sector has prospered from the COVID-19 epidemic. The advent of genetic engineering, which modifies human DNA, and organoid technology, which creates the three-dimensional structure of the tissue from originating stem cells, are two of the most significant strides in stem cell research during COVID-19. The advent of genetic engineering, which modifies human DNA, and organoid technology, which creates the three-dimensional structure of the tissue from stem cells, have been two of the most important strides in stem cell research during Covid-19. This element had a favourable effect on the world market for cancer stem cells. Additionally, there has been an increase in the use of allogeneic stem cell therapy and hematopoietic cell transplantation (HCT), particularly among cancer patients who have Covid-19 infections.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2019-2032 |
| Base year considered | 2021 |
| Forecast period | 2022-2032 |
| Segments covered | By Cancer, By Mode Of Action, By Transplantation, By Application, By End User |
| Regions covered | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
| Companies Covered | AbbVie Inc., Advanced Cell Diagnostics Inc., Bionomics, BioNTech, BioTime Inc., Caladrius Biosciences Inc., Celgene Corp., ExCellThera, Gamida Cell, Irvine Scientific, Lonza, MacroGenics, Inc., Menarini Group, Merck KGaA, Mereo BioPharma, Miltenyi, Biotec, PromoCell GmbH, Propanc Biopharma, Silicon Biosystems, Sino Biological Inc., Thermo Fisher Scientific Inc., ViaCyte Inc.
|
Global Cancer Stem Cells Market Segmentation:
By Caner: Based on the Caner, Global Cancer Stem Cells Market is segmented as; Acute Leukemia, Aplastic Anemia, Chronic Lymphocytic Leukemia, Osteopetrosis.
By Mode Of Action: Based on the Mode Of Action, Global Cancer Stem Cells Market is segmented as; Targeted Cancerous Stem Cells {By Anti-CSC Therapeutics (Pathway Inhibitors, Surface Marker Based, Immuno-evasion and Targeting Tumour Microenvironment, Nanoparticle-based Therapies), Products (Cell-Culturing, Cell-Separation, Cell-Analysis, Molecular Analysis)}, Stem Cell Based Cancer Therapy (Autologous SC Transplant, Allogeneic SC Transplant).
By Transplantation: Based on the Transplantation, Global Cancer Stem Cells Market is segmented as; Allogeneic Stem Cell Therapy, Autologous Stem Cell Therapy.
By Application: Based on the Application, Global Cancer Stem Cells Market is segmented as; Blood Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer.
By End User: Based on the End Use, Global Cancer Stem Cells Market is segmented as; Hospitals and surgical laboratories, Cell banks and tissue banks, Pharmaceutical and biomedical companies.
By Region: Due to improvements in healthcare infrastructure and strong reimbursement policies across the region, North America had the substantial share, accounting for more than two-fifths of the worldwide cancer stem cell market. On the other hand, the Asia-Pacific area will have the fastest growth in the following years. This is because the governments of China, Japan, and India are developing regulations for the development of stem cell research facilities and investing in healthcare infrastructure.
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1 Research data source
2.1.1 Secondary data
2.1.2 Primary data
2.1.3 SPER’s internal database
2.1.4 Premium insight from KOL’s
2.2 Market size estimation
2.2.1 Top-down and Bottom-up approach
2.3 Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity, and Challenges analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2. COVID-19 Impacts of the Global Cancer Stem Cells Market
5. Market variables and outlook
5.1. SWOT analysis
5.1.1 Strengths
5.1.2 Weaknesses
5.1.3 Opportunities
5.1.4 Threats
5.2. PESTEL analysis
5.2.1 Political landscape
5.2.2 Economic landscape
5.2.3 Social landscape
5.2.4 Technological landscape
5.2.5 Environmental landscape
5.2.6 Legal landscape
5.3. PORTER’S five forces analysis
5.3.1 Bargaining power of suppliers
5.3.2 Bargaining power of Buyers
5.3.3 Threat of Substitute
5.3.4 Threat of new entrant
5.3.5 Competitive rivalry
5.4. Heat map analysis
6. Global Cancer Stem Cells Market, By Cancer, 2019-2032 (USD Million)
6.1. Acute Leukemia
6.2. Aplastic Anemia
6.3. Chronic Lymphocytic Leukemia
6.4. Osteopetrosis
7. Global Cancer Stem Cells Market, By Mode Of Action, 2019-2032 (USD Million)
7.1 Targeted Cancerous Stem Cells
7.1.1 By Anti-CSC Therapeutics
7.1.1.1 Pathway Inhibitors
7.1.1.2 Surface Marker Based
7.1.1.3 Immuno-evasion and Targeting Tumour Microenvironment
7.1.1.4 Nanoparticle-based Therapies
7.1.2 Products
7.1.2.1 Cell-Culturing
7.1.2.2 Cell-Separation
7.1.2.3 Cell-Analysis
7.1.2.4 Molecular Analysis
7.2 Stem Cell Based Cancer Therapy
7.2.1 Autologous SC Transplant
7.2.2 Allogeneic SC Transplant
8. Global Cancer Stem Cells Market, By Transplantation, 2019-2032 (USD Million)
8.1. Allogeneic Stem Cell Therapy
8.2. Autologous Stem Cell Therapy
9. Global Cancer Stem Cells Market, By Application, 2019-2032 (USD Million)
9.1. Blood Cancer
9.2. Breast Cancer
9.3. Cervical Cancer
9.4. Colorectal Cancer
9.5. Lung Cancer
9.6. Prostate Cancer
10. Global Cancer Stem Cells Market, By End Use, 2019-2032 (USD Million)
10.1 Cell Banks and Tissue Banks
10.2 Hospital and Surgical Laboratories
10.3 Pharmaceutical and Biomedical Companies
11. Global Cancer Stem Cells Market, By Region, 2019-2032 (USD Million)
11.1 North America
11.1.1. United States
11.1.2. Canada
11.1.3. Mexico
11.2 Europe
11.2.1. Germany
11.2.2. United Kingdom
11.2.3. France
11.2.4. Italy
11.2.5. Spain
11.2.6. Rest of Europe
11.3 Asia-Pacific
11.3.1. China
11.3.2. Japan
11.3.3. India
11.3.4. Australia
11.3.5. South Korea
11.3.6. Rest of Asia-Pacific
11.4 South America
11.4.1. Brazil
11.4.2. Argentina
11.4.3. Rest of South America
11.5 Middle East & Africa
11.5.1. Kingdom of Saudi Arabia
11.5.2. United Arab Emirates
11.5.3. Rest of Middle East & Africa
12. Company Profiles
12.1 AbbVie Inc.
12.1.1. Company details
12.1.2. Financial outlook
12.1.3. Product summary
12.1.4. Recent developments
12.2 Advanced Cell Diagnostics Inc.
12.2.1. Company details
12.2.2. Financial outlook
12.2.3. Product summary
12.2.4. Recent developments
12.3 Bionomics
12.3.1. Company details
12.3.2. Financial outlook
12.3.3. Product summary
12.3.4. Recent developments
12.4 BioNTech
12.4.1. Company details
12.4.2. Financial outlook
12.4.3. Product summary
12.4.4. Recent developments
12.5 BioTime Inc.
12.5.1. Company details
12.5.2. Financial outlook
12.5.3. Product summary
12.5.4. Recent developments
12.6 Caladrius Biosciences Inc.
12.6.1. Company details
12.6.2. Financial outlook
12.6.3. Product summary
12.6.4. Recent developments
12.7 Celgene Corp.
12.7.1. Company details
12.7.2. Financial outlook
12.7.3. Product summary
12.7.4. Recent developments
12.8 ExCellThera
12.8.1. Company details
12.8.2. Financial outlook
12.8.3. Product summary
12.8.4. Recent developments
12.9 Gamida Cell
12.9.1. Company details
12.9.2. Financial outlook
12.9.3. Product summary
12.9.4. Recent developments
12.10 Irvine Scientific
12.10.1. Company details
12.10.2. Financial outlook
12.10.3. Product summary
12.10.4. Recent developments
12.11 Lonza
12.11.1. Company details
12.11.2. Financial outlook
12.11.3. Product summary
12.11.4. Recent developments
12.12 MacroGenics Inc.
12.12.1. Company details
12.12.2. Financial outlook
12.12.3. Product summary
12.12.4. Recent developments
12.13 Menarini Group
12.13.1. Company details
12.13.2. Financial outlook
12.13.3. Product summary
12.13.4. Recent developments
12.14 Merck KGaA
12.14.1. Company details
12.14.2. Financial outlook
12.14.3. Product summary
12.14.4. Recent developments
12.15 Mereo BioPharma
12.15.1. Company details
12.15.2. Financial outlook
12.15.3. Product summary
12.15.4. Recent developments
12.16 Miltenyi Biotec
12.16.1. Company details
12.16.2. Financial outlook
12.16.3. Product summary
12.16.4. Recent developments
12.17 PromoCell GmbH
12.17.1. Company details
12.17.2. Financial outlook
12.17.3. Product summary
12.17.4. Recent developments
12.18 Propanc Biopharma
12.18.1. Company details
12.18.2. Financial outlook
12.18.3. Product summary
12.18.4. Recent developments
12.19 Silicon Biosystems
12.19.1. Company details
12.19.2. Financial outlook
12.19.3. Product summary
12.19.4. Recent developments
12.20 Sino Biological Inc.
12.20.1. Company details
12.20.2. Financial outlook
12.20.3. Product summary
12.20.4. Recent developments
12.21 Thermo Fisher Scientific Inc.
12.21.1. Company details
12.21.2. Financial outlook
12.21.3. Product summary
12.21.4. Recent developments
12.22 VIaCyte Inc.
12.22.1. Company details
12.22.2. Financial outlook
12.22.3. Product summary
12.22.4. Recent developments